Wegovy tablets Ireland: EU approval and what it means

Important: this article provides general health and regulatory information only. It is not a medical diagnosis or personal treatment advice. Prescription medicines are not suitable for everyone, and a qualified prescriber and pharmacist should assess individual circumstances. Last reviewed 21 August 2026.

The short answer: are Wegovy tablets available in Ireland?

Wegovy tablets are authorised in the European Union, including Ireland, but EU approval is not the same as confirmed Irish pharmacy availability. On 15 July 2026, the European Commission granted marketing authorisation for once-daily oral semaglutide under the Wegovy brand for eligible adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.

At the time this article was reviewed, no confirmed public Irish launch date, Irish retail price or HSE reimbursement decision for the oral tablet had been announced through the official Irish sources reviewed. Novo Nordisk has said it is committed to launching the tablet in more countries in the second half of 2026, but that statement should not be read as a confirmed availability date for an individual pharmacy or patient in Ireland. The distinction is straightforward: authorisation makes a medicine eligible to be placed on the Irish market, while launch, supply, price and reimbursement determine whether and how patients can actually access it.

Weight management in Ireland deserves a better conversation

The need for thoughtful, evidence-based weight management is clear. The Department of Health says that 56% of people in Ireland were living with overweight or obesity in 2025, and Healthy Ireland's 2024 survey found self-reported overweight or obese measurements in 63% of men and 50% of women. Behind those numbers are people with different health histories, needs, budgets and goals. Obesity is a complex chronic disease, not a simple question of personal effort.

The Central Statistics Office's Irish Health Survey found the highest reported obesity prevalence in adults aged 55 to 64, at 30.6% among women and 29.3% among men in that age group, while advising caution when comparing survey waves because collection methods and timing can differ. A meaningful weight management conversation in Ireland includes nutrition, movement, sleep, emotional wellbeing, medical history, access to care and, for some people, prescribed treatment.

What is the Wegovy tablet?

Wegovy contains semaglutide, a medicine in the GLP-1 receptor agonist class. The oral formulation is a once-daily tablet, developed as an alternative to weekly injections for some clinically eligible adults, not as an over-the-counter wellness product. The European Medicines Agency (EMA) recommended the oral formulation for adults with a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² to below 30 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, high cholesterol, cardiovascular disease or obstructive sleep apnoea. As with injectable Wegovy, it is intended to be used together with diet and physical activity.

The tablet is prescription-only, and the EMA states it is intended for adults rather than the adolescent population for which the injectable formulation may be used in defined circumstances. In practical terms, the oral tablet is taken once daily and the established injection is given once weekly. As of 21 August 2026, the tablet is EU-authorised but its Irish launch, price and reimbursement are not publicly confirmed, whereas injectable Wegovy is already authorised in Ireland as a prescription-only, pharmacy-only medicine.

Why the EU approval matters

The European Commission's decision is a significant regulatory milestone. It creates the first EU-authorised oral GLP-1 option for weight management and gives clinicians and patients the prospect of another treatment format. For some people, a daily tablet may be more acceptable or practical than a weekly injection. Formulation choice, however, is only one part of the decision. A prescriber still needs to consider clinical eligibility, health history, other medicines, pregnancy plans, possible side effects, treatment goals and whether a person can follow the dosing routine safely and consistently.

The approval also changes the market conversation in Ireland. Until now, public attention has centred largely on injection pens. Oral semaglutide for weight management could broaden choice over time, but it will also raise new questions about supply, private cost, public reimbursement, patient counselling and safe follow-up.

What do the clinical data show?

The EMA's review describes a 64-week phase 3 study involving 307 adults with obesity, or overweight plus at least one weight-related comorbidity. Participants received oral Wegovy or placebo alongside a reduced-calorie diet and increased physical activity. People taking the tablet had a mean body-weight reduction of 13.61%, compared with 2.18% for placebo, and 76.3% achieved at least 5% weight loss compared with 30.5% on placebo.

These are study results, not a promise about what will happen for an individual. Treatment response can vary significantly, and sustainable outcomes also depend on tolerability, continuity of care, lifestyle support and what happens after any treatment change or discontinuation.

How is the tablet taken?

The oral formulation has a specific administration routine. The EMA says it is taken once daily on an empty stomach after at least eight hours of fasting, and that patients should wait 30 minutes before eating, drinking or taking other oral medicines. The UK regulator's authorisation describes gradual dose escalation from 1.5 mg through 4 mg and 9 mg to 25 mg daily, with at least one month at each dose. Exact treatment instructions must come from the prescriber and the approved product information available at the time of supply.

This matters because a tablet is not automatically a simpler clinical option. The route avoids injections, but the timing routine and possible interactions with other oral medicines still require an informed discussion with a prescriber and pharmacist.

Safety, side effects and ongoing care

Like other GLP-1 medicines, oral semaglutide can cause side effects. The EMA identified gastrointestinal effects as the most common, including nausea, diarrhoea, constipation, abdominal pain, dyspepsia and vomiting, noting that these mainly occurred at the start of treatment.

The HSE advises that obesity medicines should only be taken on prescription and with healthcare-professional oversight. Before starting treatment, a doctor may consider weight history, BMI, weight-related complications, other conditions, other medicines and possible side effects, with regular check-ups to assess whether treatment is still appropriate and effective. A responsible approach to GLP-1 medicines in Ireland is not simply about access, it is about access with assessment, education, monitoring and continuity of care.

What happens next in Ireland?

The next phase is commercial and healthcare-system implementation. Before Wegovy tablets can become a routine option in Ireland, several things need to align: a local market launch, reliable wholesaler and pharmacy supply, Irish pricing, prescriber awareness, patient counselling and any future reimbursement decisions.

In summary, the tablet is authorised for Ireland because the European Commission's marketing authorisation applies across EU member states. That does not mean an Irish pharmacy holds stock today, no confirmed public Irish price was identified at the review date, and reimbursement is a separate national decision that should not be assumed from EU approval. Wegovy remains a prescription-only medicine in every case.

Frequently asked questions

Are Wegovy tablets available in Ireland right now? They are authorised in the EU, including Ireland, but a confirmed Irish retail launch date has not been publicly announced at the time of this review. Do not assume that EU approval means local stock, an Irish price or reimbursement.

Will I need a prescription for Wegovy tablets? Yes. Wegovy is prescription-only. A clinician must assess whether it is appropriate for an individual patient, and a pharmacist has a role in safe supply and counselling.

Is the Wegovy tablet suitable for everyone who wants to lose weight? No. The approved indication is for clinically eligible adults with obesity, or overweight plus at least one weight-related comorbidity, alongside diet and physical activity. A prescriber must decide whether it is safe and appropriate for the individual.

Is the tablet better than the injection? Neither option is automatically better for every person. The most appropriate choice depends on clinical assessment, treatment history, side effects, daily routine, preference and access.

Can I buy prescription weight-management medicines online? The HPRA states that it is illegal to sell prescription medicines online in Ireland, and advises people to obtain prescription medicines from a registered source under healthcare-professional care rather than from unregulated online sellers or social-media accounts.

A more useful future for weight management in Ireland

The oral Wegovy tablet is an important development, but the bigger opportunity is better care. The future should not be framed as a race for the newest medicine. It should be a system in which patients can access respectful assessment, clinically appropriate treatment, reliable supply, honest information, realistic expectations and continuing support. Until Irish availability is formally confirmed, the responsible message is simple: follow official updates, avoid unregulated sellers and make decisions with a qualified healthcare professional.

Sources

European Medicines Agency, first oral GLP-1 treatment for weight management; European Commission approval announcement (Novo Nordisk, 15 July 2026); Department of Health public consultation on a new national obesity strategy; Healthy Ireland Survey 2024; CSO Irish Health Survey main results 2025; HPRA authorised medicine record for Wegovy and HPRA guidance on the dangers of buying prescription medicines online; HSE guidance on obesity medicines; UK Government announcement of the first GLP-1 tablet for weight loss approved in the UK.

Stay well